Effect of luteinizing hormone on follicle stimulating hormone-activated paracrine signalling in rat ovary

C.D. Smyth, F. Miró, C. M. Howles and S. G. Hillier

Reproductive Endocrinology Laboratory, University of Edinburgh Centre for Reproductive Biology, 37 Chalmers Street, Edinburgh EH3 9EW, UK and 1 Ares Services SA, 15 bis Chemin des Mines, CH 1211 Geneva 20, Switzerland

Introduction

Urinary follicle stimulating hormone (FSH) preparations lacking significant contamination with luteinizing hormone (LH) can induce pre-ovulatory follicular development with minimal increases in ovarian oestrogen secretion when given to patients with World Health Organization (WHO) type I anovulatory infertility whose endogenous LH levels are too low to measure (Couzinet et al., 1988; Shoham et al., 1991). However, in patients with detectable endogenous LH, treatment with ‘pure’ FSH induces normal follicular maturation and oestrogen secretion (Shoham et al., 1994). This type of response usually occurs when FSH is given to stimulate multiple follicular development following pituitary desensitization with a gonadotrophin-releasing hormone (GnRH) agonist (e.g. in assisted reproduction procedures (Edelstein et al., 1990) or in patients with WHO type II anovulatory infertility (Sagle et al., 1991)).

It has been known for more than 50 years that both FSH and LH are necessary to stimulate pre-ovulatory follicular development and oestadiol synthesis (Fevold, 1941; Greep et al., 1942). According to the two-cell, two-gonadotrophin model of oestrogen synthesis (Armstrong and Dorrington, 1979), FSH acts on granulosa cells to induce aromatase activity without oestrogen secretion, whereas LH alone stimulated thecal androgen synthesis and androgen secretion. When the total rhLH dose was fixed at 1 IU, giving rise to an unmeasurably low serum concentration of rhLH, additional treatment with rhFSH (30–72 IU) dose-dependently stimulated serum androgen concentrations as well as oestrogen concentrations. The ~2.0 kb-sized P-450<sub>cth</sub> mRNA transcript was undetectable in the ovaries of untreated control animals but was abundant in the ovaries of positive controls treated with 15 IU of pregnant mare serum gonadotrophin. Treatment with 1 IU of rhLH alone barely induced a P-450<sub>cth</sub> mRNA signal and treatment with 30 IU of rhFSH alone was completely ineffective. However, combined treatment with 1 IU of rhLH and 30 IU of rhFSH markedly enhanced the P-450<sub>cth</sub> mRNA signal to a level approaching the positive control. Since P-450<sub>cth</sub> mRNA is expressed exclusively in theca cells, which do not possess FSH receptors, we conclude that (i) rhFSH upregulates thecal P-450<sub>cth</sub> mRNA and hence follicular androgen synthesis via granulosa-on-theca paracrine signalling, and (ii) tonic stimulation by rhLH is required to facilitate thecal responsiveness to this rhFSH-activated paracrine signal(s).

Key words: androgen/cytochrome P-450<sub>cth</sub>/follicle stimulating hormone/luteinizing hormone/oestrogen
signalling to be manifest in vivo. Here we report experiments that directly confirm this hypothesis.

Materials and methods

Human recombinant gonadotrophins

The rhFSH was GONAL-F™ (Serono Laboratories UK Ltd, Welwyn Garden City, Herts, UK) with an in-vivo bioactivity of 13.096 IU FSH/mg (rat ovarian weight gain assay). The rhLH (Serono) had an in-vivo bioactivity of 13.018 IU LH/mg (rat ventral prostate weight gain assay).

Animals and experimental design

In-vivo effects of rhFSH and rhLH were tested in female Wistar rats hypophysectomized at 21 days of age by the supplier (Charles River UK Ltd, Margate, Kent, UK). Gonadotrophins (x) was injected s.c. in 100 μl of phosphate-buffered saline (PBS) containing 0.1% (w/v) bovine serum albumin (BSA) (ICN Biochemicals, High Wycombe, Bucks, UK). Four 12-hourly injections were given starting at the age of 25 days. The treatments were rhFSH (total dose 30 or 72 IU/animal) and/or rhLH (total dose 1 or 10 IU/animal). Negative controls received injections of vehicle alone and positive controls received a single injection (15 IU) of pregnant mare serum gonadotrophin (PMSG; Sigma Chemicals Ltd, Poole, Dorset, UK). Each experimental and control treatment group contained at least five animals, and all experiments were done at least twice.

Recovery of tissue and serum

Approximately 12 h after the last injection (48 h after initiating treatment), animals were killed by carbon dioxide asphyxiation. The ovaries and uterus were removed, dissected free of fat and extraneous tissues and weighed on an electronic balance (Cahn TA 4100; Cahn, Cerritos, CA, USA). Ovaries were used for subsequent analysis of oestradiol content by radioimmunoassay, as described below. The granulosa cells were incubated in 0.5 ml serum-free medium with or without human FSH (LER 8/116; 900 IU FSH/mg, -0.5 IU LH/mg) at a concentration of 30 ng/ml and/or 1 μM testosterone (Sigma). All treatments were done in triplicate. Incubation was for 48 h at 37°C, after which the medium was collected and stored frozen at -20°C for subsequent analysis of androgen content by radioimmunoassay, as described below. The granulosa cells were incubated in 0.5 ml of serum-free medium with or without human FSH (LER 8/116; 900 IU FSH/mg, -0.5 IU LH/mg) at a concentration of 30 ng/ml and/or 1 μM testosterone (Sigma). All treatments were done in triplicate. Incubation was for 48 h at 37°C, after which the medium was collected and stored frozen at -20°C for subsequent analysis of oestradiol content by radioimmunoassay, as described below.

Androstenedione assay

The amount of androstenedione in serum and spent culture medium was determined by radioimmunoassay (Hillier et al., 1991b). The androstenedione antiserum was rabbit anti-androst-4-ene-3,17-dione-7α-carboxyethylthioether-BSA. Major cross-reactions were androstenedione, 100%; androstene, 46.3%; 5α-androstane-3,17-dione, 50%; testosterone, 37%; and <0.5% for all other steroids tested. The inter- and intra-assay precision was <15% (coefficient of variation), with a sensitivity (minimum detectable dose) of 0.3 nmol/l.

Oestradiol assay

The amount of oestradiol in serum and spent culture medium was determined by radioimmunoassay (Hillier et al., 1981). The oestradiol antiserum was donkey K3 anti-oestradiol-17-hemisuccinyl-BSA (provided by Dr G.Read, Tenovus Institute, Cardiff, UK). Major cross-reactions were oestradiol-17β, 100%; oestrone, <1%; and <0.5% for all other steroids tested. The inter- and intra-assay precision was <15% (coefficient of variation), with a sensitivity of 0.2 nmol/l.
FSH and LH assays

rhFSH and rhLH in hypophysectomized rat serum were measured by specific immunoradiometric assays (Serono FSH MAIAclone™ and Serono LH MAIAclone™ supplied by Intereset, Wokingham, Berks, UK). Assay sensitivities were 0.25 mIU FSH/ml and 0.15 mIU LH/ml. Serum samples were analysed as a single batch with an intra-assay precision of ~3%.

Northern analysis of cytochrome P-450<sub>cl7a</sub> mRNA

Frozen tissue (whole ovaries) was homogenized in an ice-cold solution containing 4 M guanidium thiocyanate, 24 mM sodium citrate, 0.5% (w/v) sarcosyl and 0.1 M β-mercaptoethanol (all from Sigma). Total RNA was extracted with phenol–chloroform (Chomczynski and Sacchi, 1987) and size-fractionated by electrophoresis in 1.2% agarose gels containing 2.2 M formaldehyde. RNA molecular weight markers (Gibco) were run alongside samples on each gel and ethidium bromide staining was used to check the uniformity of sample loading. RNA was transferred onto nylon membranes (Hybond-N; Amersham International, Aylesbury, Bucks, UK) in 20X sodium citrate/sodium chloride (SSC), by capillary blotting. cDNA probe to rat P-450<sub>cl7a</sub> mRNA (full-length cytochrome P-450<sub>C</sub><sup>|7a</sup>; generously donated by Dr J. Ian Mason) (Fevold et al, 1989) was labelled with [32P]dCTP by random priming (Megaprime kit; Amersham). Prehybridization was carried out for 1–2 h at 42°C in 5X saline/sodium phosphate/EDTA (SSPE), 5X Denhardt’s solution, 18.5% (v/v) formamide and 0.5% (w/v) sodium dodecyl sulphate (SDS). Hybridization was carried out overnight in the same buffer containing ~1×10<sup>6</sup> cpm/ml of probe. The membranes were then washed at 65°C for ~1 h in each of three different solutions containing 1% SDS and decreasing salt concentrations (2X, 1X and 0.5X SSC). The membranes were then exposed to Kodak XAR-5 for 1–3 days at −70°C using an intensifying screen.

Statistics

Analysis of variance with the Newman–Keuls test was used to analyse differences between experimental and control observations. Differences assigned a P value of <0.05 were regarded as statistically significant.

Results

Effect of rhFSH and rhLH administration in vivo on serum hormone concentrations

Serum FSH, LH, oestradiol and androstenedione concentrations in hypophysectomized immature female rats treated with rhFSH and/or rhLH are shown in Figure 1. The circulating FSH concentration following 48 h of treatment increased to 350–400 IU/l following 72 IU of rhFSH (Figure 1a). At 1 IU of rhLH, serum LH remained undetectable but at 10 IU of rhLH, it rose to ~17 IU/l (Figure 1b). Serum oestradiol was unmeasurable if either rhFSH or rhLH was given alone. However, when given in combination each gonadotrophin dose-dependently increased oestradiol (Figure 1c). Serum androstenedione was increased dose-dependently by rhLH alone (Figure 1d). Treatment with 30 IU of rhFSH alone did not

Fig. 1. Effect of treatment with recombinant human follicle stimulating hormone (rhFSH) and/or recombinant human luteinizing hormone (rhLH) in vivo on plasma concentrations of (a) rhFSH, (b) rhLH, (c) oestradiol and (d) androstenedione. Hypophysectomized immature female rats were treated with vehicle alone or rhFSH (total dose 30–72 IU) and/or rhLH (total dose 1–10 IU) given as four 12-hourly s.c. injections. At 48 h after beginning treatment, the animals were killed and blood was sampled from the posterior vena cava and analysed by specific immunoradiometric assay (rhFSH and rhLH) or specific radioimmunoassay (oestradiol and androstenedione). Results from a representative experiment are expressed as mean ± SE (n ≥ 5). Statistics: a denotes significant (P < 0.01) effect due to rhFSH treatment versus corresponding treatment without rhFSH; b (P < 0.01) and c (P < 0.05) denote significant increase due to rhLH versus corresponding treatment without rhLH.
stimulate androstenedione, but at 72 IU rhFSH increased androstenedione on average 2- to 3-fold relative to control. The lower dose of rhFSH had no effect on the androstenedione response to 1 IU of rhLH but increased the response to 10 IU rhLH ~2-fold; 72 IU of rhFSH increased the androstenedione responses to both 1 and 10 IU rhLH by a similar magnitude (Figure 1d).

**Effect of rhFSH and rhLH administration in vivo on ovarian and uterine weights**

Ovarian and uterine weights following treatment with a fixed dose (30 IU) of 20 rhFSH in the presence of 1 and 10 IU rhLH are shown in Figure 2. Neither dose of rhLH alone significantly affected ovarian weight. However, rhFSH alone increased ovarian weight ~2-fold, and this response was further enhanced by combining rhFSH treatment with either dose of rhLH (Figure 2a). Alone, neither gonadotrophin significantly affected uterine weight, whereas both combinations of rhLH with rhFSH were stimulatory (Figure 2b). Use of 72 IU of rhFSH instead of 30 IU of rhFSH caused even greater increases in ovarian weight, without significantly affecting uterine weight unless rhLH was also present (data not shown).

**Effect of rhFSH and rhLH administration in vivo on granulosa cell aromatase activity in vitro**

Treatment with rhFSH strongly stimulated granulosa cell aromatase activity both in vivo and in vitro (Figure 3). The aromatase response to combined treatment with rhFSH (30 IU) and rhLH (1 IU) was comparable with that of rhFSH alone. Treatment with 1 IU of rhLH alone was ineffective.

**Effect of rhFSH and rhLH administration in vivo on thecal/interstitial cell androgen production in vitro**

In-vivo treatment with rhFSH (30 IU) or rhLH (1 IU) alone had no significant effect on basal or LH-responsive thecal/interstitial cell androgen production in vitro, whereas combined treatment with the same doses of rhFSH and rhLH in vivo led to a markedly enhanced androstenedione response to LH in vitro (Figure 4).

---

Fig. 2. Effect of treatment with recombinant human follicle stimulating hormone (rhFSH) and/or recombinant human luteinizing hormone (rhLH) in vivo on (a) ovarian and (b) uterine weights. Hypophysectomized immature female rats were treated with vehicle alone or vehicle containing rhFSH (total dose 30 IU) and/or rhLH (total dose 1–10 IU) given as four 12-hourly s.c. injections. At 48 h after beginning treatment the animals were killed and the ovaries and uteri were immediately removed and cleaned of all extraneous material before weighing. Results from a representative experiment are expressed as weight ± SE of a single ovary (n > 10), or weight ± SE of uterine horn (n > 5). Statistics: a denotes a significant (P < 0.01) increase due to rhFSH treatment versus corresponding treatment without rhFSH; b (P < 0.01) and c (P < 0.05) denote significant increase due to rhLH treatment versus corresponding treatment without rhLH.

Fig. 3. Effect of treatment with recombinant human follicle stimulating hormone (rhFSH) and/or recombinant human luteinizing hormone (rhLH) in vivo on granulosa cell aromatase activity. Hypophysectomized female rats were treated with vehicle alone or vehicle containing rhFSH (total dose 30 IU) and/or rhLH (total dose 1 IU) given as four 12–30-hourly s.c. injections. At 48 h after beginning treatment the animals were killed and ovaries removed for isolation of granulosa cells. Granulosa cell cultures (40 000 viable cells per well) were incubated for 48 h in serum-free medium with 1.0 U.M testosterone (aromatase substrate) in the presence or absence of rhFSH (30 ng/ml). Oestradiol in the spent culture medium was determined by radioimmunoassay. Results from a representative experiment are expressed as pmol of oestradiol produced/1000 cells/h ± SE (n = 3). Asterisks denote a significant difference due to rhFSH treatment in vivo versus the corresponding untreated control (*P < 0.01; **P < 0.05).
Effect of FSH and LH administration in vivo on ovarian P-450c17α mRNA expression

A P-450c17α mRNA signal was not detectable by Northern analysis of ovarian total RNA from vehicle-treated control animals (Figure 5). However, treatment with PMSG as a positive control induced an abundant ~2.0 kb-sized transcript. Treatment with rhLH (1 IU) alone barely stimulated the appearance of this transcript, and rhFSH (30 IU) alone was completely negative. However, in the presence of LH, FSH strongly increased the intensity of the P-450c17α mRNA signal.

Discussion

This study using recombinant (hence ‘pure’) human gonadotrophins confirms that both FSH and LH are necessary for follicular oestrogen synthesis (Fevold, 1941; Greep et al., 1942; Armstrong and Dorrington, 1979; Mannaerts et al., 1991). FSH treatment alone stimulates follicular growth and increased expression of granulosa cell P-450c17α (Fitzpatrick and Richards, 1991; Whitelaw et al., 1992), while LH acts directly to stimulate P-450c17α in the theca interna (Fortune and Armstrong, 1977; Smyth et al., 1993). Thereby the two gonadotrophins jointly regulate oestrogen synthesis.

A novelty here is that we have used recombinant human gonadotrophins and hypophysectomized animals to dissect out a paracrine (granulosa on theca) interaction that is activated by FSH and facilitated by LH. The ovarian weight, serum oestrogen/uterine weight and aromatase activity data presented here are all consistent with previously reported actions of rhFSH on ovarian oestrogen synthesis in vivo and in vitro (Mannaerts et al., 1991; Whitelaw et al., 1992). rhFSH potently stimulates ovarian weight (i.e. follicular growth) and granulosa cell aromatase activity, but oestrogen secretion (uterine weight gain) only occurs when LH activity is also given. rhLH alone does not cause ovarian weight gain or oestrogen secretion but does increase androgen secretion. Importantly, treatment with rhFSH (devoid of LH activity, and hence unable to act directly on thecal cells) dose-dependently increases the androgenic response to rhLH. Since granulosa cells are the only cells in the female body known to possess FSH receptors, this evidence strongly suggests that FSH is able to activate a granulosa-derived paracrine signal(s) that positively regulates thecal androgen synthesis. Moreover, direct stimulation with rhLH sensitizes the theca interna to this FSH-induced paracrine signal.

Unequivocal evidence that rhLH promotes thecal/interstitial responsiveness to rhFSH in vivo is provided by the demonstration that ovarian P-450c17α mRNA, shown previously to be...
C.D.Smyth et al.

located exclusively in theca/interstitial cells (Smyth et al., 1993), is only measurably increased by treatment with rhFSH if rhLH is given concurrently. Significantly, the dose of rhLH required to elicit this effect in hypophysectomized immature female rats is so low (1 IU of rhLH over 48 h) that it is not even detectable in blood using a sensitive immunoradiometric assay for human LH.

The nature of the paracrine signal activated by FSH is presently unknown. However, both IGF-I (Adashi et al., 1985) and inhibin (Hsueh et al., 1987) of granulosa cell origin are obvious possibilities. We have previously shown that gonadotrophin-induced oestriadiol biosynthesis in individually cultured rat follicles can be blocked by the presence of a neutralizing antibody to inhibin (Smyth et al., 1994). Moreover, inhibin antibody-induced blockade of oestradiol synthesis is overcome by the presence of exogenous aromatase substrate (androstenedione) in the culture medium. This strongly implicates inhibin in the paracrine mediation of FSH action on thecal androgen synthesis in the rat ovary. Since FSH also stimulates inhibin production by human granulosa cells (Hillier et al., 1991a) and inhibin promotes LH-stimulated androgen synthesis by human thecal cells (Hillier et al., 1991b), the implications of the present results for human reproductive physiology seem obvious.

It is known from previous studies of LH action on gonadal cells that <1% of LH receptors need to be occupied to elicit maximal steroidogenic responses in vitro (Catt and Dufau, 1977). The present demonstration that unmeasurably low, endogenous concentrations of LH are sufficient to facilitate FSH-responsive ovarian androgen synthesis further emphasizes the minimal, albeit crucial, dependence that the ovary has on LH to undertake apparently normal rates of follicular oestrogen synthesis.

These experimental results could have potential clinical relevance. If they can be extrapolated to humans, they offer a means to interpret the effects of 'pure' FSH preparations when used to stimulate ovarian function in women with various types of infertility, as follows.

(i) Using FSH alone in conjunction with GnRH-agonist suppression of pituitary function to stimulate multiple follicular development so that eggs can be collected for assisted reproduction procedures. Repeated exposure of pituitary gonadotropes to GnRH-agonists causes 'down-regulation' involving micro-aggregation of GnRH receptors and internalization of agonist—receptor complexes, such that LH and FSH concentrations in blood fall to near undetectable amounts. Despite a dearth of endogenous LH, administration of 'pure' FSH alone usually stimulates multiple follicular development and oestrogen secretion to degrees comparable with those achieved when FSH and LH (i.e. human menopausal gonadotrophin) are given simultaneously. If FSH activates a paracrine mechanism that up-regulates LH-responsive androgen synthesis, and hence oestriadiol synthesis, it becomes evident why FSH is effective in spite of the minimal LH concentrations present when routine GnRH-agonist regimens are employed. It also follows that long-term or 'deep' pituitary suppression could make patients less responsive to FSH.

(ii) Patients with WHO group II type infertility. Women with anovulatory infertility but who are not devoid of endogenous LH often receive ovulation induction therapy, with or without pituitary down-regulation. Such patients frequently overrespond to FSH therapy and, if care is not taken, they can develop ovarian hyperstimulation. Many of these women have polycystic ovaries (PCO) associated with high basal serum LH concentrations. Thecal cells from PCO follicles undertake higher rates of androgen synthesis than those of 'normal' follicles of a similar size (Gilling-Smith et al., 1993). Since androgens enhance FSH-stimulated granulosa cell function (including inhibin production) in vitro (Hillier et al., 1991a), and inhibin and/or other granulosa cell factors have the potential to promote LH-responsive thecal androgen synthesis (Hillier et al., 1991b), reciprocal paracrine signalling between LH-stimulated thecal cells and FSH-stimulated granulosa cells could bring about follicular hypersensitivity to FSH.

(iii) Patients suffering from a complete LH deficiency (i.e. WHO group I type infertility). When such patients are given ovarian stimulation therapy, the usual aim is to induce monovulation so that conception can occur in vivo. A normal pattern of oestrogen production is integral to a successful therapeutic outcome. An adequate ovarian response to 'pure' FSH therefore requires simultaneous administration of LH, either at doses that stimulate thecal androgen synthesis directly or in reduced amounts sufficient to promote the indirect responsiveness of thecal cells to FSH demonstrated here.

Acknowledgements

We thank Dr J. Ian Mason (Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA) for providing the P-450(M20 cDNA and Dr L.E. Reichert, Jr (Albany Medical College, Albany, NY, USA) for providing the human pituitary gonadotrophin preparations. Supported by the UK Medical Research Council (Programme Grant no. 8929853).

References


FSH-stimulated paracrine signalling requires LH


Received on May 19, 1994; accepted on August 30, 1994